We already knew from the UP clinical trial that Brilacidin's systemic absorption was insignificant, when administered from, uh, the bottom up. It will be interesting to see if there is more significant absorption when it travels through more of the digestive system. But obviously there are no safety concerns, given that the third cohort was approved.